CSBio CSBio

X
[{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Formosa Pharmaceuticals"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Formosa Pharmaceuticals"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"AimMax Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Formosa Pharmaceuticals"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Eyenovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Formosa Pharmaceuticals"},{"orgOrder":0,"company":"Formosa Pharmaceuticals","sponsor":"Crist\u00e1lia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Formosa Pharmaceuticals Announces Licensing Agreement with Crist\u00e1lia, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Formosa Pharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, Cristália gets exclusive Brazilian rights for the commercialization of APP13007 (clobetasol propionate ophthalmic nanosuspension) for the treatment of inflammation and pain following ocular surgery.

            Lead Product(s): Clobetasol Propionate

            Therapeutic Area: Neurology Product Name: APP13007

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cristália

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 26, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the acquisition, Eyenovia has gained the exclusive U.S. rights to distribute and sell APP13007 (clobetasol propionate ophthalmic nanosuspension), a potent steroid for reducing the inflammation and pain associated with ocular surgery, which is under review by FDA.

            Lead Product(s): Clobetasol Propionate

            Therapeutic Area: Neurology Product Name: APP13007

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eyenovia

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition August 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            APP13007 (clobetasol propionate ophthalmic nanosuspension) is expected to provide ophthalmologists and ocular surgery patients with a compelling, rapid and sustained, and more convenient postoperative anti-inflammatory and pain relief solution.

            Lead Product(s): Clobetasol Propionate

            Therapeutic Area: Neurology Product Name: APP13007

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: AimMax Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 05, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            There were 26.5% of subjects who showed sustained anterior chamber cell (ACC) count = 0 (inflammation free) from post-operative day 8 (POD8) through POD15 in the APP13007 (clobetasol propionate) arm as compared to 5.1% in the placebo arm (p<0.001).

            Lead Product(s): Clobetasol Propionate

            Therapeutic Area: Neurology Product Name: APP13007

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: AimMax Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 12, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Data showed statisticallly-significant and clinically-meaningful improvement of inflammation and pain with twice-daily APP13007 compared to matching placebo, a regimen that is being evaluated in ongoing Phase 3 studies.

            Lead Product(s): Clobetasol Propionate

            Therapeutic Area: Neurology Product Name: APP13007

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: AimMax Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY